The INSM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INSM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The INSM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View INSM Detailed Price Forecast - CNN Money||View INSM Detailed Summary - Google Finance|
|View INSM Detailed Summary - Yahoo! Finance||View INSM Stock Research & Analysis - Zacks.com|
|View INSM Trends & Analysis - Trade-Ideas||View INSM Major Holders - Barrons|
|View INSM Call Transcripts - NASDAQ||View INSM Breaking News & Analysis - Seeking Alpha|
|View INSM Annual Report - CompanySpotlight.com||View INSM OTC Short Report - OTCShortReport.com|
|View INSM Fundamentals - TradeKing||View INSM SEC Filings - Bar Chart|
|View Historical Prices for INSM - The WSJ||View Performance/Total Return for INSM - Morningstar|
|View the Analyst Estimates for INSM - MarketWatch||View the Earnings History for INSM - CNBC|
|View the INSM Earnings - StockMarketWatch||View INSM Buy or Sell Recommendations - MacroAxis|
|View the INSM Bullish Patterns - American Bulls||View INSM Short Pain Metrics - ShortPainBot.com|
|View INSM Stock Mentions - StockTwits||View INSM Stock Mentions - PennyStockTweets|
|View INSM Stock Mentions - Twitter||View INSM Investment Forum News - Investor Hub|
|View INSM Stock Mentions - Yahoo! Message Board||View INSM Stock Mentions - Seeking Alpha|
|View Insider Transactions for INSM - SECform4.com||View Insider Transactions for INSM - Insider Cow|
|View INSM Major Holdings Summary - CNBC||View Insider Disclosure for INSM - OTC Markets|
|View Insider Transactions for INSM - Yahoo! Finance||View Institutional Holdings for INSM - NASDAQ|
|View INSM Stock Insight & Charts - FinViz.com||View INSM Investment Charts - StockCharts.com|
|View INSM Stock Overview & Charts - BarChart||View INSM User Generated Charts - Trading View|
Free Technical Research on Insmed and Three More Biotech Equities
Posted on Friday July 13, 2018
On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).
See what the IHS Markit Score report has to say about Insmed Inc.
Posted on Tuesday July 03, 2018
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC
Posted on Friday June 15, 2018
Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Division of Antimicrobial Products of the U.S. Food and Drug Administration (FDA) has notified the company of a planned advisory committee meeting to review data supporting Insmed’s New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). “Currently there are no approved therapies for this rare, progressive and potentially fatal disease, representing a significant unmet need,” commented Will Lewis, President and Chief Executive Officer of Insmed. The Company has previously announced that the FDA accepted and considered the NDA for ALIS filed on May 27, 2018.
Insmed to Present at Three June Conferences
Posted on Thursday June 07, 2018
BRIDGEWATER, N.J., June 07, 2018-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will present at the ...